DDInter150 DDInter1738
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection. Azathiprine was granted FDA approval on 20 March 1968.
Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity relative to non-engineered anti-CD19 antibodies.[L15292,A191829] The CD19 surface protein is highly expressed on the surface of B-cells, where it appears to play a role in enhancing B-cell receptor signaling. Its relative ubiquity across different stages of B-cell development, including pre-B and mature B-lymphocytes, as well as its presence in several B-cell malignancies (e.g. chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL)) has made it a desirable target in the treatment these B-cell malignancies. Tafasatimab is designed to bind to and block the activity of the CD19 surface antigen, which ultimately results in the lysis of B-cells (both healthy and malignant). Having previously received Breakthrough Therapy, Fast Track, and Orphan designations from the FDA, tafasatimab-cxix (Monjuvi®) received an accelerated approval on July 31st, 2020, for the treatment of relapsed or refractory DLBCL in adult patients who cannot receive autologous stem cell transplants. It must be used in combination with [lenalidomide], as this combination results in greater efficacy as compared to either agent alone.
Azathioprine {u} (Compound) downregulates {v} (Gene) MCM3
MCM3 {u} (Gene) is downregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tafasitamab
Azathioprine {u} (Compound) upregulates {v} (Gene) NUCB2
NUCB2 {u} (Gene) is downregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tafasitamab
Azathioprine {u} (Compound) downregulates {v} (Gene) PSRC1
PSRC1 {u} (Gene) is downregulated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Tafasitamab
Azathioprine {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tafasitamab
Azathioprine {u} (Compound) binds {v} (Gene) TPMT
TPMT {u} (Gene) is upregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tafasitamab
Azathioprine {u} (Compound) causes {v} (Side Effect) Haemoglobin
Haemoglobin {u} (Side Effect) is caused by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tafasitamab
Azathioprine {u} (Compound) causes {v} (Side Effect) Haemoglobin
Haemoglobin {u} (Side Effect) is caused by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Tafasitamab
Azathioprine {u} (Compound) treats {v} (Disease) multiple sclerosis
multiple sclerosis {u} (Disease) is treated by {v} (Compound) Fingolimod
Fingolimod {u} may lead to a major life threatening interaction when taken with {v} Tafasitamab
Azathioprine {u} (Compound) upregulates {v} (Gene) ABHD4
ABHD4 {u} (Gene) is upregulated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Tafasitamab
Azathioprine (Compound) downregulates MCM3 (Gene) and MCM3 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Tafasitamab
Azathioprine (Compound) upregulates NUCB2 (Gene) and NUCB2 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Tafasitamab
Azathioprine (Compound) downregulates PSRC1 (Gene) and PSRC1 (Gene) is downregulated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Tafasitamab
Azathioprine (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Tafasitamab
Azathioprine (Compound) binds TPMT (Gene) and TPMT (Gene) is upregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Tafasitamab
Azathioprine (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Tafasitamab
Azathioprine (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Tafasitamab
Azathioprine (Compound) treats multiple sclerosis (Disease) and multiple sclerosis (Disease) is treated by Fingolimod (Compound) and Fingolimod may lead to a major life threatening interaction when taken with Tafasitamab
Azathioprine (Compound) upregulates ABHD4 (Gene) and ABHD4 (Gene) is upregulated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Tafasitamab